Theodore Pincus, MD; Isabel Castrejon, MD; Yusuf Yazici, MD
Potential Conflicts of Interest: Dr. Pincus: Consultancy: Bristol-Myers Squibb, Genentech, UCB. Dr. Yazici: Consultancy: Abbott, Bristol-Myers Squibb, Genentech, Pfizer, Horizon, UCB; Grants/grants pending: Bristol-Myers Squibb, Genentech, Janssen.
Pincus T, Castrejon I, Yazici Y. Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis. Ann Intern Med. 2012;157:299. doi: 10.7326/0003-4819-157-4-201208210-00018
Download citation file:
Published: Ann Intern Med. 2012;157(4):299.
TO THE EDITOR:
The article by Bakker and colleagues (1) presents impressive control of disease activity in patients with rheumatoid arthritis (RA), which ironically may have attenuated the apparent treatment effect of prednisone. Overall, 67% of patients who received no prednisone had no erosions—only 11% fewer than the 78% of patients treated with 10 mg/d of prednisone for 2 years, albeit a statistically significant difference. The strongest treatment effects that were maintained over 2 years involved patient functional status, which generally is more significant than laboratory and radiographic data to predict work disability and mortality in patients with RA (2).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only